close
Add to watchlist
Immunomedics Inc (IMMU) Healthcare, Biotechnology & Drugs
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases. Its lead product candidate is epratuzumab, a Phase IIb clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin's lymphoma; and Veltuzumab, which is in Phase I/II clinical study for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and for patients with ITP. The company's other products include IMMU-102, a Y-90-labeled epratuzumab product candidate, which is in Phase I/II clinical study for the treatment of patients with non-Hodgkin's lymphoma; and IMMU-107 or PAM4 labeled with Y-90, a humanized monoclonal antibody product, which is in Phase I/II dose-escalation trials for the treatment of pancreatic cancer. ImmunomedicsÂ’ products also comprise Milatuzumab, a Phase I/II multicenter clinical trial product for the treatment of multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia; and Labetuzumab, a Phase II clinical trail product that targets carcinoembryonic antigen. It also develops two platform technologies, including Dock-and-Lock method of fusing proteins and antibodies, and antibody-drug conjugation technology. In addition, the company markets and sells LeukoScan, a diagnostic product used for a range of infectious and inflammatory diseases. Immunomedics distributes its products in the United States and Europe. It has a license and collaboration agreement with Nycomed to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.39 |
| Volume | 182935 |
| Volume Avg | 292692 |
| 52 Week High | 4.47 |
| 52 Week Low | 2.85 |
| PE | 26.56 |
| PE (group average) | 39 |
| EPS Year | 0.13 |
| EPS change Q/Q | -100% |
| EPS change Q/Q Yr ago | 1000% |
| EPS change Q/Q next Q est | -11.11% |
| EPS change Y/Y | -1000% |
| REV change Q/Q | 10% |
| REV change Q/Q Yr ago | -89.72% |
| EPS next Q est | -0.09 |
| EPS next Y est | -0.40 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |